AMD

ABI-201 aims to prevent dry AMD and other retinal disorders in patients.

The data was included in the paper, titled “Sozinibercept Combination Therapy for Neovascular Age-Related Macular Degeneration: Phase 2b Study Subgroup Analysis by Lesion Type.”

Ixo-vec utilizes a proprietary vector capsid, AAV.7m8, carrying an aflibercept coding sequence under the control of a proprietary expression cassette and is designed to be administered as a one-time intravitreal injection.

If approved, the drug will be branded as LYTENAVA.

RPESC-RPE-4W is a cell product derived from adult retinal pigment epithelial stem cells.

AVT06 is Alvotech’s proposed biosimilar to Eylea (aflibercept) 2mg.

Panelists discuss how longer-acting treatments will enable extended intervals between visits while requiring careful adjustment of monitoring protocols and clinic workflows to balance reduced treatment burden with maintaining adequate disease surveillance.

The topline results from the COAST trial is anticipated in early Q2 of 2025.

PST-611, a first in class non-viral vectorized therapy expressing human transferrin, a highly potent iron regulator.

How modern tools may lead to customized AMD treatment plans

Panelists discuss how loading doses remain crucial for treatment-naive patients to achieve rapid disease control, while patients switching therapies may require modified approaches based on their prior treatment response and disease activity.

Panelists discuss how real-world evidence provides crucial insights into treatment effectiveness across diverse patient populations and clinical settings while highlighting challenges in maintaining clinical trial protocols’ stringent adherence and monitoring in everyday practice.

Researchers screened for outcomes such as the presence of retinal diseases including age-related macular degeneration and retinal vein occlusion

David S. Boyer, MD will present data from the sozinibercept Phase 2b wet AMD trial.

The 36-week trial was a randomized, double-masked, parallel-group, active-controlled, multicenter evaluating CLS-AX (axitinib injectable suspension) in participants with neovascular age-related macular degeneration.

PRISM evaluates 4D-150, a potential backbone therapy designed to provide multi-year sustained delivery of anti-VEGF (aflibercept and anti-VEGF-C) from the retina with a single, safe, intravitreal injection.

Results were published from the phase 3 QUASAR trial and the extension study of the phase 3 PULSAR trial.

Panelists discuss how both medications demonstrate favorable safety profiles in clinical trials, with aflibercept 8 mg benefiting from extensive 2-mg safety data, while acknowledging the need to monitor intraocular pressure due to increased injection volume, particularly in at-risk patients.

Panelists discuss how faricimab’s dual inhibition of Ang-2 provides additional benefits in vascular stability and inflammation reduction beyond VEGF-A suppression alone, potentially leading to improved durability and treatment outcomes in selected patients.

The implant was tested in eyes of patients with bilateral age-related macular degeneration who underwent cataract surgery

The data will be presented virtually at Angiogenesis, Exudation, and Degeneration 2025 on February 8 and February 10, 2025.

Results from the study assisted Notal Vision in receiving De Novo authorization from the US FDA for the SCANLY Home OCT in 2024.

The company offers year-round educational services on the conditions, using this month in particular to guide patients to needed resources.